Former President and Chief Executive Officer · ROCKET PHARMACEUTICALS, INC. (RCKT)

David Southwell

A named executive officer of ROCKET PHARMACEUTICALS in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$2,742,506

Salary $35,412Stock awards $0

FY2017: $1,267,082

3rd of 4 named executive officers at Rocket Pharmaceuticals by FY2018 total.

4 named officers on file for ROCKET PHARMACEUTICALS, FY2018

David Southwell’s pay file — $29

  • 2 fiscal years of pay, line by line
  • RCKT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ROCKET PHARMACEUTICALS’s whole pay program stands against its peers

  • ROCKET PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RCKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2019 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get David Southwell’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Southwell compensation by year

ROCKET PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$479,454$35,412
Bonus$239,862$0
Stock awards$533,750$0
Option awards$0$1,719,373
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$14,016$987,721
Total$1,267,082$2,742,506

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 30, 2019, accession 0001140361-19-008016, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-19-008016. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2019.

$1.3M
$2.7M
FY17
FY18
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option40,000—$18.75

Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2018 proxy (filed April 30, 2019)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-03Other—150,000$0.00204,522
2026-06-18Grant or award derivative—64,860$0.0064,860
2026-06-18Grant or award—22,862$0.0054,522
2025-06-18Grant or award—30,000$0.0031,660

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ROCKET PHARMACEUTICALS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Gaurav ShahChief Executive Officer$6,375,752
Kinnari PatelChief Operating Officer and EVP, Development$2,991,073
David Southwell · this pageFormer President and Chief Executive Officer$2,742,506
Jonathan SchwartzChief Medical Officer and SVP, Clinical Development$1,356,675

Board service

ROCKET PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$53,750$84,900——$138,650
FY2024$44,620—$359,990$0$404,610
FY2023$40,000—$359,992$0$399,992
FY2022$40,000—$324,995$0$364,995
FY2021$37,500—$341,629$0$379,129

Each year as the company reported it in ROCKET PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: ROCKET PHARMACEUTICALS pays directors a $40,000 cash retainer and $360,000 in equity. As stated in ROCKET PHARMACEUTICALS's FY2025 proxy.

Committees

Compensation (Chair) · Nominating/Governance (Chair)

The full ROCKET PHARMACEUTICALS compensation record

free company brief

This page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ROCKET PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Southwell's compensation dossier · One-time report. No refunds.